HCM
ADVM

Highbridge Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Highbridge Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,000
Closed -$2.32M – 877
2018
Q1 		$2.32M Hold
40,000
– – 0.04% 421
2017
Q4 		$1.4M Buy
+40,000
New +$1.32M 0.03% 461

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Highbridge Capital Management's ADVM Position: Q1 2019 in Review

Highbridge Capital Management sold out of Adverum Biotechnologies (ADVM) in Q1 2019, closing a stake of 2,603 shares — an estimated $82K sold.

Highbridge Capital Management first reported a position in ADVM in Q4 2016 and held it in 9 quarters. The position peaked at $12.2M in Q1 2018. 83 funds tracked by Wall St. Rank hold ADVM as of Q1 2019.

  • Highbridge Capital Management reported no remaining Adverum Biotechnologies position as of Q1 2019 after selling out during the quarter.
  • Highbridge Capital Management sold 2,603 Adverum Biotechnologies shares in Q1 2019, an estimated $82K.
  • Highbridge Capital Management first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 9 quarters.
  • Highbridge Capital Management's Adverum Biotechnologies position peaked at $12.2M in Q1 2018.
  • 83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2019.

Based on Highbridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.